14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
June 2025 in “Medical Science Journal for Advance Research” Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
December 2012 in “http://isrctn.org/>” January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
5 citations
,
November 2022 in “Genetics selection evolution” Low-coverage sequencing is a cost-effective way to find genetic factors affecting rabbit wool traits.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” 5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
1 citations
,
January 2024 in “Pediatric Endocrinology Diabetes and Metabolism” Cinacalcet may help treat hereditary vitamin D resistant rickets safely.
3 citations
,
January 2022 in “Scientific Reports” A new treatment called SAMiRNA-AR68 increases hair count in people with hair loss, showing similar results to existing treatments but without side effects.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
55 citations
,
December 2021 in “BMC Veterinary Research” Certain genes in Iranian sheep are linked to wool production and heat adaptation.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
January 2013 in “Annals of Ayurvedic Medicine” Abrus precatorius seed oil promotes hair growth and has antifungal properties.
Avicennia marina extract can significantly promote hair growth in androgenic alopecia patients.
January 2022 in “Turkiye Klinikleri Journal of Dermatology” The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
5 citations
,
April 2024 in “JAAD International” AI can accurately measure hair loss severity in alopecia areata.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
November 2025 in “Frontiers in Medicine” The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
AnnoPharma effectively identifies substances causing adverse drug reactions in medical abstracts.
5 citations
,
December 2018 in “Frontiers in Endocrinology” Differences in androgen receptor expression and tissue properties may lead to higher cryptorchidism risk in certain rats.